Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
Retail Sales Month on Month for August came in at -1.6% more than 3 times worse than the -0.5% forecast.
People are tightening their belts.
I suspect this will counter any positivity from the increased holding RNS.
Yup. I expected some director buys prior to blackout period if they expected results to be good. Even a few £100k would send a positive message. They mustn’t be confident that this is the bottom.
I predicted we’d break this Friday, but it came the next trading day. Not support has gone, I can’t see the bottom. Fair value only 12p.
Next resistance 44p which I expect we’ll see before the 21st Sept. About then, I expect a rise into results from the shorts derisking.
The quote below is a direct lift from the ONS report. Yes, up MoM. But, it ‘continues in a broad downtrend in online sales since the highs of Feb 2021.’
Might be worth reading the Joules RNS too and noting the profit margin impact from discounting goods. Likely to also impact here.
FWIW I’m long on Boo with a 62p average since the Hedge fund bought a few weeks back.
Also note we’re still on a general downtrend.
“ The proportion of retail sales online rose to 26.3% in July 2022, from 25.3% in June 2022; despite this pick-up, it continues a broad downward trend since its peak in February 2021 (37.5%), but remains above pre-pandemic levels (19.8% in February 2020).”
Mainly on food though. Good that online sales rose again; however, less being spent on clothing.
“ Non-food stores sales volumes fell by 0.7% over the month because of falls in other non-food stores (negative 1.5%), and clothing stores (negative 1.2%).”
ONS report.
Finally the news we’ve been waiting for! Surprised there’s no comments on here about the RNS???
No doubts we’ll see a few attempts at valuation in the coming days.
Trinity Delta view: FDA clearance of the Parsortix system in mBC has been a clear focus for many investors. Achievement of this gold standard validation could transform ANGLE, with a potential near-term acceleration in revenues from the Pharma Service business, in which we see significant value. Longer-term, this could also drive revenues in mBC. We continue to believe ANGLE is well positioned to capitalise on growing recognition of the utility of CTC analysis in investigating protein markers on cancer cells, without the limitations of ctDNA (circulating tumour DNA) liquid biopsy (inapplicable to proteins) or tissue biopsies (unsuitable for longitudinal monitoring). We value ANGLE at £506m ($658m), or 215p/share with significant upside once Parsortix’s positioning becomes clearer.
https://app.researchpool.com/provider/trinity-delta/angle-plc-agl-trinity-delta-lighthouse-angle-JISjIQkF7d?utm_source=dlvr.it&utm_medium=twitter
Great interview with so many interesting points. This is literally a game changer for cancer treatment. There’ll be a stream of RNS’ over the next few weeks and months, but I wouldn’t be surprised by a takeover before the end of the year.
Where do people see support? Was looking to top up, but technicals pointing towards a further move south. Anything below 5000 is a buy IMO.
https://m.uk.investing.com/equities/asos-plc-technical
US Ban... yup, going to be a bad day for those long. I think this, coupled with a likely online sales tax in the budget will see a big dip for Boo. Great buying op, but I’d wait until after the budget.
Kamani will need to resign to restore II confidence after this shambles.
Where did you get £10m from? I thought it was £5m.
The 2019 trading update wasn’t published until Feb 2020. So I’m expecting last years to be a few weeks away. Hopefully news prior to then.
If you’re so sure why don’t you go short NI? Or maybe you did at 22p? Now you’re on margin call and doing you’re upmost to get the price down? You might be right, sentiment may turn, but with E3 being next week I can’t see it being as soon as you hope. Don’t like to see anyone getting wiped out, so you should maybe consider closing before then.